Patent applications published 14 September 2011
Selected patent applications from the weekly European Patents Bulletin
- A method for the purification of substituted cyclopen-2-en-1-one congeners and substituted q,3-cyclopentadione congeners from a complex mixture using countercurrent separation
Metaproteomics 2364083*
- Low dose lipic acid pharmaceutical compsns and methods
Encore Health 2364084*
- Releasable cationic lipids for nucleic acid delivery systems
Enzon Pharmaceuticals 2364085*
- Novel antithrombitic diadenosine tetraphosphates and related analogues
Glsynthesis 2364086*
- 7-hydroxybenzimidazole-4-yl-methanone derivatives and PBK inhibitors containing the same
Oncotherapy Science 2364087*
- Heterobicyclic aryl sphingosine 1-phosphate analogues
Biogen Idec 2364089*
- Drug or dermatological compsn containing an avocado peptide complex for treating and preventing pruritus
Laboratoires Expanscience 2364135*
- Cosmetic use of skin cell autophagy activators
Société Industrielle Limousine d’Application Biologique Dite SILAB 2364136*
- Pharmaceutical suspension
Alcon Research 2364137*
- Palonosetron formulation
Teva Pharmaceutical Industries 2364138*
- NGNA compsns and methods of use
Life Science Nutrition 2364139*
- Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
Advance Holdings 2364140*
- Compacted moxiflacin
Ratiopharm 2364141*
- Compsns of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
Arena Pharmaceuticals 2365142*
- Osmotic tablet with a compressed outer coating
McNeill-PPC 2364143*
- Dosage form for insertion into the mouth
Nal Pharmaceuticals 2364144*
- Dosage forms for the rapid and sustained elevation of gastric pH
Pozen 2364145*
- Medicament and method of diagnosis
The University of Sheffield 2364146*
- Compsns comprising 1-aryl-pyrazole alone or in combination with formamidine for the treatment of parasitic infection
Merial 2364147*
- Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
DLFZ Deutsches Krebsforschungs-zentrum 2364148*
- TNIK inhibitor and the use
National Cancer Center, Tokyo; Carna Biosciences 2364149*
- Treatment with alpha-7 sensitive ligands
Targacept 2364150*
- Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
Concert Pharmaceuticals 2364151*
- Methods of preparation and use of marrow infiltrating lymphocytes (MILS)
The Johns Hopkins University 2364152*
- Chitosan derivatives to treat animals or optimise animal health
Synedgen 2364153*
- Compsns and methods for treating matrix metalloproteinase 9 (MMP-9)-mediated conditions
Revalesio 2364154*
- Activation and aggregation of human platelets and formation of platelet gels by nanosecond pulsed electric fields
Eastern Virginia Medical School; Old Dominion University 2364155*
- Modified protozoan expressing at least two variable surface proteins (VSO), a vaccine comprising it and procedures, uses and methods thereof
Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Buenos Aires; Universidad Catòlica de Còrdoba 2364156*
- Plant extract compsns for affecting sleep
Viva Pharmaceutical 2364157*
- Phytocomplex from bergamot fruit, process of manufacture and use as dietary supplement and in the pharmaceutical field
Herbal & Antioxidant Derivatives 2364158*
- Deuterated macrocyclic inhibitors of viral NS3 protease
Concert Pharmaceuticals 2364159*
- Compsns containing interleukin-1 and peptides
United Technologies 2364160*
- Compsns containing satiogens and methods of use
Satiogen Pharmaceuticals 2364161*
- Compsns and methods for diagnosing and treating B-CLL
Yeda Research and Development Company at the Weizmann Institute of Science 2364162*
- Compsn comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
CentoClone International 2364163*
- Method and compsn for enhancement of male erectile function
Adams, Kenneth 2364164*
- Antidotes for factor XA inhibitors and methods of using the same in combination with blood coagulating agents
Portola Pharmaceuticals 2364165*
- Suppression of cancer
Syntaxin 2364166*
- Method for production of pH stable enveloped viruses
Avir Green Hills Biotechnology Research 2364167*
- Extended length botulinum toxin for human or mammalian use
Botulinum Toxin Research Associates 2364168*
- An apparatus and method to deliver a sterile, filled syringe to a user
Ceramatec 2364169*
- Distributed phthalazine disubstituted hedgehog pathway antagonists
Eli Lilly 2364185*
- Method for the production of adipic acid
Rhodia Operations 2364286*
- Process for the preparation of non-genotoxic diacetylrhein (diacerein) and formulations comprising non-genotoxic diacetylrhein
Evultis 2364287*
- Processing method in the production of (math)acrylic acid alkyl esters
Evonik Stockhausen 2364288*
- Process for the preparation of arylamine compounds
Univation Technologies 2364290*
- 1,2-diaminocyclohexane and chemical process
Invista Technologies 2364291*
- Amide inhibitors of renin
Auspex Pharmaceuticals 2364292*
- Novel microbicides
Syngenta Participations 2364293*
- 3-(benzylamino)-pyrrolidine derivatives and their use as NK-3 receptor antagonists
F Hoffmann-La Roche 2364295*
- Pyrrolidines
Pfizer 2364296*
- Compounds, pharmaceutical compsn and methods for use in treating metabolic disorder
Euroscreen 2364297*
- Quinoline compound and pharmaceutical compsn
Otsuka Pharmaceutical 2364298*
- Bis [O-(14-benzoylaconine-8-yl)] esters
Université Victor Segalen Bordeaux 2 2364299*
- Dimeric 1-arylpyrazole derivatives
Merial 2354200*